These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 25079338)
1. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338 [TBL] [Abstract][Full Text] [Related]
2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169 [TBL] [Abstract][Full Text] [Related]
3. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787 [TBL] [Abstract][Full Text] [Related]
4. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727 [TBL] [Abstract][Full Text] [Related]
5. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115 [TBL] [Abstract][Full Text] [Related]
6. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Petersen SL; Peyton M; Minna JD; Wang X Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11936-41. PubMed ID: 20547836 [TBL] [Abstract][Full Text] [Related]
7. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Mak PY; Mak DH; Mu H; Shi Y; Ruvolo P; Ruvolo V; Jacamo R; Burks JK; Wei W; Huang X; Kornblau SM; Andreeff M; Carter BZ Apoptosis; 2014 Apr; 19(4):698-707. PubMed ID: 24337870 [TBL] [Abstract][Full Text] [Related]
8. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Chromik J; Safferthal C; Serve H; Fulda S Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825 [TBL] [Abstract][Full Text] [Related]
10. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541 [TBL] [Abstract][Full Text] [Related]
11. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells. Liu H; Liao R; He K; Zhu X; Li P; Gong J Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228 [TBL] [Abstract][Full Text] [Related]
12. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079 [TBL] [Abstract][Full Text] [Related]
14. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC. Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358 [TBL] [Abstract][Full Text] [Related]
15. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686 [TBL] [Abstract][Full Text] [Related]
16. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244 [TBL] [Abstract][Full Text] [Related]
17. Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Tchoghandjian A; Jennewein C; Eckhardt I; Rajalingam K; Fulda S Cell Death Dis; 2013 Mar; 4(3):e564. PubMed ID: 23538445 [TBL] [Abstract][Full Text] [Related]
18. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979 [TBL] [Abstract][Full Text] [Related]
19. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728 [TBL] [Abstract][Full Text] [Related]